Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.
Baker JC Jr, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL. Baker JC Jr, et al. Among authors: pilie pg. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884-90. doi: 10.1158/1055-9965.EPI-07-2696. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18708376 Free PMC article.
Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF.
Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC Jr, Ibarra C, Brander DM, Paisie C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL. Bean GR, et al. Among authors: pilie pg. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6834-41. doi: 10.1158/1078-0432.CCR-07-0407. Clin Cancer Res. 2007. PMID: 18006786
CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.
Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL. Vasilatos SN, et al. Among authors: pilie pg. Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):901-14. doi: 10.1158/1055-9965.EPI-08-0875. Epub 2009 Mar 3. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19258476 Free PMC article.
Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data.
Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF 3rd, Wulfkuhle JD, Liotta LA, Lem S, Baker JC Jr, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL. Pilie PG, et al. Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):476-82. doi: 10.1158/1055-9965.EPI-10-0847. Epub 2011 Jan 17. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21242333 Free PMC article.
Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.
Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF 3rd, Wulfkuhle J, Liotta LA, Lem S, Baker JC Jr, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL. Ibarra-Drendall C, et al. Among authors: pilie pg. Breast Cancer Res Treat. 2012 Apr;132(2):487-98. doi: 10.1007/s10549-011-1609-9. Epub 2011 Jun 7. Breast Cancer Res Treat. 2012. PMID: 21647677 Free PMC article.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators. Smith MR, et al. Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4. Lancet Oncol. 2022. PMID: 35131040 Free PMC article. Clinical Trial.
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. McGrail DJ, et al. Among authors: pilie pg. Ann Oncol. 2021 May;32(5):661-672. doi: 10.1016/j.annonc.2021.02.006. Epub 2021 Mar 15. Ann Oncol. 2021. PMID: 33736924 Free PMC article.
Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.
Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, Robichaux CC, Villarreal MF, Weldon JA, Woodson AH, Pilie PG, Fuller GN, Waguespack SG, Matin SF. Jonasch E, et al. Among authors: pilie pg. Lancet Oncol. 2018 Oct;19(10):1351-1359. doi: 10.1016/S1470-2045(18)30487-X. Epub 2018 Sep 17. Lancet Oncol. 2018. PMID: 30236511 Free PMC article. Clinical Trial.
39 results